Trial results

Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction

NCT06557811 on ClinicalTrials.gov · last registry update 2024-08-26

88 participants. Its estimated completion date, 1 September 2024, has passed with no update to the record. Primary outcome, as filed: Measurement of pericardial adipose tissue at 180 days. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

UNKNOWN

Phase

P4

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

University of Sao Paulo General Hospital

Sponsor type

Other

Enrollment

88

Started

2024-09-01

Primary completion

2024-09-01 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Measurement of pericardial adipose tissue at 180 days

Conditions studied

Diabetic Patients · Acute Myocardial Infarction

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.